Latest Proof Of Concept News

Kinetiko Energy’s Brakfontein test wells delivered sustained gas flows well above the commercial threshold used in its prior reserve assessment, strengthening the case for a staged South African development. But the company ended the year with just A$478,634 in cash and restricted funds, prompting its auditor to flag a material going concern uncertainty.

Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.

Ovanti sharply reduced its quarterly operating cash outflow to A$491,096, helped by higher customer receipts and cost reductions. But with only A$227,000 in cash, the ASX-listed fintech remains dependent on further funding, operating receipts and uncertain legal recoveries.

G50 has extended the known strike of its Golconda gold-silver system to more than 1.8km, with shallow high-grade results from the Golden Eagle target. The ASX-listed explorer also finished the quarter with A$25.778 million in cash after a placement backed by Hancock Prospecting.

icetana AI has started FY27 with a sharp lift in recurring revenue and quarterly sales, while its Antara Core platform reached its first commercial deployment. The progress came alongside higher operating cash outflows and a $3.9 million cash balance.

Mitchell Services delivered a sharp earnings acceleration in FY27’s opening quarter, helped by stronger rig utilisation, higher revenue per shift and a $3.4 million insurance benefit. Ten additional underground rig contracts provide a potential route to 80 operating rigs, although higher capital spending and softer cash conversion temper the picture.

Antimony Resources has begun processing about 200 tonnes of Chinantla material through its Tecomatlán plant in Mexico, marking its first plant-scale campaign on third-party feed. The result that matters next is not the start-up itself, but whether independent assays validate a saleable concentrate and support continuous operations.

InteliCare Holdings Limited (ASX:ICR) used FY2026 to move from pilot projects into contracted deployment, led by an estimated $8.8 million five-year agreement with mecwacare. Revenue and customer receipts more than doubled, although the company remains loss-making and reliant on disciplined rollout execution and further funding.

Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.

FortifAI says independent verification found its NOL8 AI Data Plane delivered up to 118 times more data per infrastructure dollar than Google RE2 at the highest workload tested. The result supports NOL8’s commercialisation push, while also triggering the vesting of 52,516,667 Class C Performance Rights.

TZ Limited is still seeking funding after failing to complete its shortfall share placement, with $1.3 million in debt and vendor obligations due. The company says a management restructure, cost cuts and commercial opportunities could improve cash generation, but several forecasts remain conditional.

SRJ Technologies has moved its Dubai Petroleum relationship from proof of concept into revenue-generating field operations, with an indicative opportunity pipeline of up to US$4.4 million. Angola mobilisation and an expanded emissions programme add near-term activity, although several opportunities remain uncommitted.